Aug 25, 2020 7:00am EDT Sutro Biopharma Earns Clinical Supply Milestone Payment from Merck KGaA, Darmstadt, Germany for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors
Aug 11, 2020 7:00am EDT Sutro Biopharma Announces Two Executive Promotions to Vice President of Quality and Vice President of Manufacturing
Aug 10, 2020 5:00pm EDT Sutro Biopharma to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Aug 06, 2020 7:00am EDT Sutro Biopharma Reports Second Quarter 2020 Financial Results and Provides Business Highlights and Developments
Jun 22, 2020 7:00am EDT Sutro Biopharma Presents New Preclinical Data at 2020 AACR Virtual Annual Meeting II Suggesting Synergy between its STRO-002 Antibody-Drug Conjugate and Immune Checkpoint Inhibitors Resulting in Tumor Regression and Adaptive Anti-Tumor Immunity
Jun 09, 2020 7:00am EDT Sutro Biopharma to Present New Preclinical Data on its STRO-002 Antibody-Drug Conjugate at the Upcoming AACR 2020 Virtual Meeting on June 22, 2020
May 21, 2020 7:15am EDT Sutro Biopharma Expands Senior Management with the Additions of Vice President of Clinical Development and Vice President of Finance and Controller
May 21, 2020 7:00am EDT Sutro Biopharma Adds Two Exceptional Leaders to Advisory Boards-- Carlos Paya, MD, PhD, and Lainie Martin, MD
May 14, 2020 4:01pm EDT Sutro Biopharma Announces Closing of $98.0 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
